TScan Therapeutics Inc — Cash Flow (NASDAQ:TCRX) | MetaTrader

Open full chart

Financials

Overview 성명 Statistics

Quarterly Annual

Cash from operating activities -48.68 M-66.5 M-61.36 M-110.82 M-135.32 M -135.32 M Cash from investing activities -9.94 M-4.22 M-60.76 M-52.61 M109.37 M 109.37 M Cash from financing activities 189.67 M29.36 M135.44 M208.76 M-336 K -336 K Free cash flow -58.62 M-70.73 M-64.5 M-114.65 M-139.73 M -139.73 M

뉴스

Buy 2 ‘Strong Buy’ Biotech Stocks With 400%+ Upside, According to Wall Street - TipRanks.com

Tscan Therapeutics Q1 실적, 수익 예상치를 넘어

Tscan Therapeutics earnings beat by $0.09, revenue topped estimates

TScan Therapeutics, Inc. (TCRX) Reports Q4 Loss, Misses Revenue Estimates

TScan completes enrollment in trial cohort, receives FDA clearance

Recursion Pharmaceuticals (RXRX) Reports Q4 Loss, Beats Revenue Estimates

Agios Pharmaceuticals (AGIO) Reports Q4 Loss, Beats Revenue Estimates

Sutro Biopharma (STRO) Surges 11.9%: Is This an Indication of Further Gains?

Roivant Sciences Ltd. (ROIV) Reports Q3 Loss, Misses Revenue Estimates

Tracking Baker Brothers Portfolio – Q3 2025 Update (NASDAQ:INCY)

Tscan 테라퓨틱스, ASH 행사 후 BTIG ’중립’ 등급 유지

Tscan Therapeutics stock holds Neutral rating at BTIG after ASH event